Concentric Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Concentric Wealth Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.36M	Hold	46,526	–	–	0.33%	66
2024 Q2	$1.08M	Buy	46,526 +10,040	+28%	+$193K	0.28%	69
2024 Q1	$749K	Hold	36,486	–	–	0.2%	82
2023 Q4	$783K	Hold	36,486	–	–	0.23%	78
2023 Q3	$753K	Hold	36,486	–	–	0.25%	78
2023 Q2	$1.08M	Hold	36,486	–	–	0.34%	69
2023 Q1	$841K	Buy	36,486 +8,519	+30%	+$234K	0.28%	72
2022 Q4	$778K	Hold	27,967	–	–	0.27%	74
2022 Q3	$858K	Hold	27,967	–	–	0.32%	73
2022 Q2	$823K	Hold	27,967	–	–	0.28%	74
2022 Q1	$900K	Hold	27,967	–	–	0.26%	78
2021 Q4	$1.25M	Hold	27,967	–	–	0.35%	73
2021 Q3	$1.41M	Buy	27,967 +8,621	+45%	+$486K	0.43%	69
2021 Q2	$1.52M	Sell	19,346 -5,092	-21%	-$315K	0.46%	69
2021 Q1	$1.4M	Sell	24,438 -1,713	-7%	-$115K	0.46%	70
2020 Q4	$2.19M	Buy	26,151 +5,000	+24%	+$302K	0.81%	49
2020 Q3	$758K	Sell	21,151 -3,000	-12%	-$90.3K	0.33%	72
2020 Q2	$584K	Hold	24,151	–	–	0.27%	77
2020 Q1	$423K	Buy	+24,151	New	+$504K	0.23%	80

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Concentric Wealth Management's DNLI Position: Q3 2024 in Review

Concentric Wealth Management held its Denali Therapeutics (DNLI) position steady in Q3 2024 at 46,526 shares worth $1.36M. The position accounts for 0.33% of the portfolio, ranked #66.

Concentric Wealth Management first reported a position in DNLI in Q1 2020 and has held it in 19 quarters since. The position peaked at $2.19M in Q4 2020. 217 funds tracked by Wall St. Rank hold DNLI as of Q3 2024.

Concentric Wealth Management held 46,526 shares of Denali Therapeutics worth $1.36M as of Q3 2024.
Concentric Wealth Management left its Denali Therapeutics share count unchanged in Q3 2024.
Denali Therapeutics made up 0.33% of Concentric Wealth Management's portfolio in Q3 2024, its #66 holding.
Concentric Wealth Management first reported a position in Denali Therapeutics in Q1 2020 and has held it in 19 quarters since.
Concentric Wealth Management's Denali Therapeutics position peaked at $2.19M in Q4 2020.
217 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2024.

Based on Concentric Wealth Management's 13F filing for Q3 2024, filed 13 Nov 2024.